EFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL (CAR-T) THERAPY IN LYMPHOMA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS

I Gede Krisna Arim Sadeva; I Gede Wikania Wira Wiguna; Ni Wayan Armerinayanti; Putu Mirah Wahyu Subagia Putri; Christo Timothy Mamangdean; Putu Ari Shanti Dewi; Kadek Meryndha Kumala Tungga; I Komang Raditya Putra Pratama; Agung Brahmanthya Nadine Kepakisan; Komang Indra Parama  Arta

doi:10.33992/meditory.v14i1.5125

Authors

I Gede Krisna Arim Sadeva Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0000-0002-9623-2310
I Gede Wikania Wira Wiguna Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0000-0001-8227-677X
Ni Wayan Armerinayanti Faculty of Medicine Warmadewa University, Indonesia https://orcid.org/0000-0003-2499-8285
Putu Mirah Wahyu Subagia Putri Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0009-0008-7356-3601
Christo Timothy Mamangdean 1Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0000-0001-8033-5756
Putu Ari Shanti Dewi Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0000-0003-3926-0099
Kadek Meryndha Kumala Tungga Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0009-0008-4864-3079
I Komang Raditya Putra Pratama Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0009-0009-9964-778X
Agung Brahmanthya Nadine Kepakisan Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0009-0005-1909-8858
Komang Indra Parama Arta Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia https://orcid.org/0009-0006-7124-9606

DOI:

https://doi.org/10.33992/meditory.v14i1.5125

Keywords:

CAR-T cell therapy, efficacy, lymphoma, safety

Abstract

Abstract

Background: Lymphoma (Hodgkin and non-Hodgkin) is a malignancy of the lymphatic system, with global prevalence reaching 2.8% and mortality rates reaching 248,700 cases each year. Therefore, Chimeric Antigen Receptor-Modified T cell therapy (CAR-T) was developed as a new approach to improve survival rates in lymphoma patients.

Objective: This study aimed to evaluate the efficacy and safety of CAR-T cell therapy in lymphoma.

Methods: PRISMA 2020 was used in the literature search and systematic review with the keywords "CAR-T Cell Therapy" and "Lymphoma". All statistical analyses were performed with R statistical software version 3.3 and MedCalc software version 22. A p-value ≤ 0.05 was considered statistically significant.

Results: There were 16 studies involving 440 patients with lymphoma. The complete response rate was 62% (95% CI 55%-65%, I² = 40%). Meanwhile, cytokine release syndrome (CRS) occurred in 73% of cases (95% CI 49%-88%, I² = 80%). The overall Immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 17% (95% CI 9%-30%, I² = 66%). There is no significant publication bias in all analyses (p-value>0.05). However, these results need to be interpreted with caution, considering the high heterogeneity in the pooled analysis results (I² > 50%).

Author Biography

Ni Wayan Armerinayanti, Faculty of Medicine Warmadewa University

Pathology Department Warmadewa University

References

1. Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol. 2022 May;15(1):57.

2. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. Med Sci (Basel, Switzerland). 2021 Jan;9(1).

3. Mafra A, Laversanne M, Gospodarowicz M, Klinger P, De Paula Silva N, Piñeros M, et al. Global patterns of non-Hodgkin lymphoma in 2020. Int J cancer. 2022 Nov;151(9):1474–81.

4. Hardianti M, Rizki S, Arkananda H, Dhyanti A, Setiawan S, Indrawati, et al. Anemia in Lymphoma Patients in Indonesia: The Prevalence and Predictive Factors. Asian Pacific J Cancer Biol. 2021 Nov;6:235–41.

5. Buechner J, Kersten MJ, Fuchs M, Salmon F, Jäger U. Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe. HemaSphere. 2018;2(1):e18.

6. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan;380(1):45–56.

7. Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018 Oct;24(10):1504–6.

8. Shargian L, Raanani P, Yeshurun M, Gafter-Gvili A, Gurion R. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis. Br J Haematol. 2022 Sep;198(5):838–46.

9. Kim J, Cho J, Yoon SE, Kim WS, Kim SJ. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. Cancer Res Treat. 2023 Jul;55(3):1031–47.

10. Qu C, Ping N, Kang L, Liu H, Qin S, Wu Q, et al. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. J Immunother. 2020 Jan;43(1):32–7.

11. Bao F, Wan W, He T, Qi F, Liu G, Hu K, et al. Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Ther. 2019 Jul;26(7–8):248–55.

12. Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020 Aug;9(16):5827–38.

13. Zhou X, Ge T, Li T, Huang L, Cao Y, Xiao Y, et al. CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma. Cancer Immunol Immunother. 2021 Aug;70(8):2379–84.

14. Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. Clin cancer Res an Off J Am Assoc Cancer Res. 2021 Jan;27(2):473–84.

15. Fan L, Wang L, Cao L, Zhu H, Xu W, Li J. Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. Front Med. 2022 Apr;16(2):285–94.

16. Zhou X, Tu S, Wang C, Huang R, Deng L, Song C, et al. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Front Immunol. 2020;11:564099.

17. Hirayama A V, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019 May;94(S1):S42–9.

18. Sun C, Shou P, Du H, Hirabayashi K, Chen Y, Herring LE, et al. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. Cancer Cell. 2020 Feb;37(2):216-225.e6.

19. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu M-F, Ivanova A, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2020 Nov;38(32):3794–804.

20. Hirayama A V, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019 Aug;134(7):636–40.

21. Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021 Nov;40(1):367.

22. Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023 Jan;7(1):32–9.

23. Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017 Dec;7(12):1404–19.

24. Zhao X, Yang J, Zhang X, Lu X-A, Xiong M, Zhang J, et al. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia. Mol Ther oncolytics. 2020 Sep;18:272–81.

25. Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021 Feb;10(3):999–1011.

26. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1403–15.

27. Qu C, Zou R, Wang P, Zhu Q, Kang L, Ping N, et al. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients. Front Immunol. 2022;13:969660.